Source link : https://www.newshealth.biz/health-news/phase-3-izokibep-study-in-hs-produces-promising-results/
AMSTERDAM — The investigational interleukin (IL)-17A inhibitor izokibep induces clear clinical responses in people with moderate to severe hidradenitis suppurativa (HS) within a few weeks of treatment, according to the results of a randomized controlled phase 3 trial presented at the European Academy of Dermatology and Venereology (EADV) 2024 Congress. One third of the participants […]
Author : News Health
Publish date : 2024-10-08 12:28:18
Copyright for syndicated content belongs to the linked Source.